Press Release

July 19, 2026 DCS-CRD Listing Compliance BSE Limited National Stock Exchange of India Limited First Floor, New Trade Wing Exchange Plaza, 5th Floor Rotunda Building, Phiroze Jeejeebhoy Towers Plot No. C/1, ‘G’ Block, Bandra- Kurla Complex Dalal Street, Fort Mumbai 400001 Bandra East Mumbai 400051 Fax No.2272 3121/2037/2039 Fax No.2659 8237/8238 Stock Code: 543213 Stock Code: ROSSARI Dear Sir/Madam, Subject.: Q1 FY27 Press Release Please find enclosed a copy of the Press Release for the Quarter ended June 30, 2026. The same may please be taken on record and suitably disseminated to all concerned. Thanking you, Yours Sincerely, For Rossari Biotech Limited Parul Gupta Company Secretary & Head - Legal Membership No.: A38895 Encl.: as above Rossari Biotech Limited Corporate Office: Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai – 400079, Maharashtra, India Rossari Biotech announces Q1 FY27 results Q1 FY27 Highest-ever quarterly Revenue of Rs. 697.2 crore, up 28% YoY Highest-ever quarterly EBITDA of Rs. 80.6 crore, up 19% YoY PAT at Rs. 35.1 crore, up 4% YoY Mumbai, July 18, 2026: Rossari Biotech Limited (Rossari), a Specialty-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries, has announced its financial results for the quarter ended June 30, 2026. Consolidated: Q1 FY27 performance overview compared with Q1 FY26 − Revenue from operations grew 28% to Rs. 697.2 crore as compared to Rs. 543.7 crore − EBITDA improved by 19% to Rs. 80.6 crore from Rs. 67.9 crore o EBITDA margin at 11.6% as against 12.5% − PAT increased by 4% to Rs. 35.1 crore from Rs. 33.6 crore − EPS (Diluted) stood at Rs. 6.3* as against Rs. 6.1* Standalone: Q1 FY27 performance overview compared with Q1 FY26 − Revenue from operations stood at Rs. 482.3 crore as against Rs. 365.8 crore, up 32% − EBITDA increased by 28% to Rs. 56.4 crore as against Rs. 43.9 crore o EBITDA margin at 11.7% as against 12.0% − PAT higher by 31% to Rs. 34.3 crore as against Rs. 26.2 crore − EPS (Diluted) stood at Rs. 6.2 as against Rs. 5.8 Note: 1) All figures, unless mentioned otherwise, are on a consolidated basis 2) * EPS not annualized Page | 1 Commenting on the performance, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said “We commenced FY27 on a strong note, delivering robust consolidated revenue growth of 28% YoY. The performance was driven by healthy momentum in the domestic business and the continued expansion of our international presence. Despite a dynamic operating environment, our diversified business model, broad-based market presence and disciplined execution enabled us to deliver growth across all our business segments. Our HPPC, TSC and AHN businesses delivered YoY growth of 28%, 28% and 27%, respectively, reflecting healthy momentum across the portfolio. Performance was supported by deeper market penetration, expansion into new applications and a higher contribution from differentiated, value-added specialty solutions across end-user industries. Our international business continued to make steady progress, supported by higher wallet share with global partners and growing acceptance of our specialty solutions across key overseas markets. During the quarter, we further strengthened our regional presence with the establishment of a greenfield blending facility in Thailand, designed to serve Southeast Asia. The facility will enhance our ability to offer customised formulations, respond swiftly to local market requirements and improve supply-chain efficiency. Over the past few years, we have made focused investments in developing new capabilities, innovation and product development. Capacity utilisation across these investments has been improving steadily, and our priority is now to drive optimal utilisation, strengthen the product portfolio and enhance operational efficiencies. Together with our robust R&D platform, these efforts will enable us to address evolving industry requirements and reinforce our competitive positioning. As we progress through FY27, we remain focused on disciplined execution, innovation and profitable growth. Supported by a healthy balance sheet, an integrated manufacturing platform and an expanding global presence, we are well-positioned to capitalise on emerging opportunities and create sustainable long-term value for all our stakeholders.” Key Developments − Strengthened Southeast Asia Presence through Thailand Facility o Established a greenfield blending facility in Thailand through the Company’s subsidiary, Unistar Thai o Installed capacity of 5,000 MTPA, with capabilities across powders, granules and liquids o Designed to offer customised formulations aligned with local market requirements − Progress on Monetisation of Non-Core Assets o Completed the sale of the Company’s Andheri office during the quarter o Marks further progress in the Company's ongoing monetisation of non-core assets, following the sale of the Kanjurmarg office in the previous quarter. Note: Home, Personal Care and Performance Chemicals (HPPC); Textile Specialty Chemicals (TSC); Animal Health and Nutrition (AHN) < Ends > Page | 2 About Rossari Biotech Limited: Rossari Biotech Limited (Rossari) (BSE: 543213, NSE: ROSSARI), is a Speciality-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries. Headquartered at Mumbai, India, the Company operates strategically located manufacturing facilities at Silvassa and Dahej. The Company offers tailor-made solutions for Home, Personal Care and Performance chemicals (HPPC), Textile speciality chemicals and Animal Health and Nutrition (AHN). With differentiated product offerings, Rossari caters to an array of applications across FMCG, Home care, Industrial Cleaning, Personal Care, Textile Speciality Chemicals, Performance Chemicals, the Animal Health and Nutrition and Pet Care businesses. The Company has an extensive and a dedicated network of distributors spread all over India. For more information, please visit www.rossari.com OR contact: Ketan Sablok Anoop Poojari / Mitesh Jain Rossari Biotech Limited CDR India Tel: +91 22 6123 3800 Tel: +91 98330 90434 / 96194 44691 Email: ketan.sablok@rossari.com Email:anoop@cdr-india.com / mitesh@cdr-india.com DISCLAIMER: Certain statements and opinions with respect to the anticipated future performance of Rossari Biotech Limited in the press release (“forward-looking statements”), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to be correct. Such forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changes in economic, political, regulatory, business or other market conditions. Such forward- looking statements only speak as at the date the press release is provided to the recipient and Rossari Biotech Limited is not under any obligation to update or revise such forward-looking statements to reflect new events or circumstances. No representation or warranty (whether express or implied) is given in respect of any information in this press release or that this press release is suitable for the recipient’s purposes. The delivery of this press release does not imply that the information herein is correct as at any time subsequent to the date hereof and Rossari Biotech Limited has no obligation whatsoever to update any of the information or the conclusions contained herein or to correct any inaccuracies which may become apparent subsequent to the date hereof. Page | 3